References of "Evrard, Brigitte"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailPréparation de complexes mebendazole-HPβCD à l'aide de polymères solubles dans l'eau et d'acides organiques
Alvarez, C; Van Hees, Thierry ULg; Piel, Géraldine ULg et al

in Annales Pharmaceutiques Françaises (2001), 59

Detailed reference viewed: 20 (1 ULg)
See detailPreparation of mebendazole HP-b-cyclodextrin complexes using water soluble polymers and organic acids
Alvarez, Covadonga; Van Hees, Thierry ULg; Piel, Géraldine ULg et al

Conference (2000, April)

Detailed reference viewed: 21 (1 ULg)
Full Text
Peer Reviewed
See detailDetermination of Albendazole and Its Main Metabolites in Ovine Plasma by Liquid Chromatography with Dialysis as an Integrated Sample Preparation Technique
Chiap, Patrice ULg; Evrard, Brigitte ULg; Bimazubute, M. A. et al

in Journal of Chromatography. A (2000), 870(1-2), 121-34

Albendazole is a benzimidazole derivative with a broad-spectrum activity against human and animal helminth parasites. In order to determine the main pharmacokinetic parameters in sheep after oral and ... [more ▼]

Albendazole is a benzimidazole derivative with a broad-spectrum activity against human and animal helminth parasites. In order to determine the main pharmacokinetic parameters in sheep after oral and intravenous administration of a new formulation of albendazole (an aqueous solution), a fully automated method was developed for the determination of this drug and its main metabolites, albendazole sulfoxide (active metabolite) and sulfone in ovine plasma. This method involves dialysis as purification step, followed by enrichment of the dialysate on a precolumn and liquid chromatography (LC). All sample handling operations were executed automatically by means of an ASTED XL system. After conditioning of the trace enrichment column (TEC) packed with octadecyl silica with pH 6.0 phosphate buffer containing sodium azide, the plasma sample, in which a protein releasing reagent (1 M HCl) containing Triton X-100 was automatically added, was loaded in the donor channel and dialysed on a cellulose acetate membrane in the static-pulsed mode. The dialysis liquid consisted of pH 2.5 phosphate buffer. By rotation of a switching valve, the analytes were eluted from the TEC in the back-flush mode by the LC mobile phase and transferred to the analytical column, packed with octyl silica. The chromatographic separation was performed at 35 degrees C and the analytes were monitored photometrically at 295 nm. Due to the differences in hydrophobic character between albendazole and its metabolites, a gradient elution was applied. The mobile phase consisted of a mixture of acetonitrile and pH 6.0 phosphate buffer. The proportion of organic modifier was increased from 10.0 to 50.1% in 12.30 min, then from 50.1 to 66.9% in 1.70 min. First, the gradient conditions and the temperature were optimised for the LC separation using the DryLab software. Then, the influence of some parameters of the dialysis process on analyte recovery was investigated. Finally, the method developed was validated. The mean recoveries for albendazole and its metabolites were about 70 and 65%, respectively. The limits of quantification for albendazole and its metabolites were 10 and 7.5 ng/ml, respectively. [less ▲]

Detailed reference viewed: 34 (0 ULg)
See detailInclusion of Piroxicam into Beta-Cyclodextrin by Means of Supercritical Carbon Dioxide: Thermal, Spectroscopic and Physicochemical Studies
Van Hees, Thierry ULg; Evrard, Brigitte ULg; Piel, Géraldine ULg et al

in Journal de Pharmacie de Belgique (2000), 55(1, Jan-Feb), 30-1

The preparation of a piroxicam-beta-cyclodextrin inclusion compound using supercritical CO2 was investigated. The solubility piroxicam in supercritical CO2 was determined. The influence of the temperature ... [more ▼]

The preparation of a piroxicam-beta-cyclodextrin inclusion compound using supercritical CO2 was investigated. The solubility piroxicam in supercritical CO2 was determined. The influence of the temperature, the pressure and the time of exposure on the inclusion rate were studied and a complete inclusion was achieved by keeping a physical mixture of piroxicam and beta-cyclodextrin (1:2.5 mol/mol) for 6 hours at 150 degrees C and 150 bar of CO2. This complex was characterised by Differential Scanning Calorimetry and Fourier Transform Infrared Spectrometry. Supercritical carbon dioxide may prove to be a novel useful complexation method of non-polar drugs into beta-cyclodextrin. [less ▲]

Detailed reference viewed: 38 (6 ULg)
Full Text
Peer Reviewed
See detailApplication of Supercritical Carbon Dioxide for the Preparation of a Piroxicam-Beta-Cyclodextrin Inclusion Compound
Van Hees, Thierry ULg; Piel, Géraldine ULg; Evrard, Brigitte ULg et al

in Pharmaceutical Research (1999), 16(12), 1864-70

PURPOSE: Piroxicam is a poorly soluble NSAID, whose solubility is enhanced when included into beta-cyclodextrin. The preparation of a piroxicam-beta-cyclodextrin inclusion compound using supercritical CO2 ... [more ▼]

PURPOSE: Piroxicam is a poorly soluble NSAID, whose solubility is enhanced when included into beta-cyclodextrin. The preparation of a piroxicam-beta-cyclodextrin inclusion compound using supercritical CO2 was investigated. METHODS: The solubility and the stability of piroxicam in supercritical CO2 were determined. Then, the influence of the temperature, the pressure and the time of exposure on the inclusion rate was studied. RESULTS: The solubility of piroxicam varied over a wide range depending on the temperature and pressure (from 0.006 to 1.500 mg/g of CO2). The temperature and the time of exposure had a great influence on the inclusion yield, while pressure did not and a complete inclusion was achieved by keeping a physical mixture of piroxicam and beta-cyclodextrin (1:2.5 mol/mol) for 6 hours at 150 degrees C and 15 MPa of CO2. This complex was characterized by Differential Scanning Calorimetry, differential solubility and Fourier Transform Infrared Spectrometry. CONCLUSIONS: Supercritical carbon dioxide may prove to be a novel useful complexation method of drugs into beta-cyclodextrin. [less ▲]

Detailed reference viewed: 61 (2 ULg)
Full Text
Peer Reviewed
See detailInfluence of Melting and Rheological Properties of Fatty Binders on the Melt Granulation Process in a High-Shear Mixer
Evrard, Brigitte ULg; Amighi, K.; Beten, D. et al

in Drug Development & Industrial Pharmacy (1999), 25(11), 1177-84

The preparation of granules by melt granulation was investigated using a laboratory-scale high-shear mixer (Pellmix PL 1/8) and binary mixtures containing lactose and different lipidic binders, namely ... [more ▼]

The preparation of granules by melt granulation was investigated using a laboratory-scale high-shear mixer (Pellmix PL 1/8) and binary mixtures containing lactose and different lipidic binders, namely, Compritol 888, Cutina HR, or Precirol ATO5. [less ▲]

Detailed reference viewed: 25 (0 ULg)
Full Text
Peer Reviewed
See detailComparison of the Iv Pharmacokinetics in Sheep of Miconazole-Cyclodextrin Solutions and a Micellar Solution
Piel, Géraldine ULg; Evrard, Brigitte ULg; Van Hees, Thierry ULg et al

in International Journal of Pharmaceutics (1999), 180(1), 41-5

The pharmacokinetics of miconazole were studied after intravenous administration to six sheep (4 mg/kg) of three aqueous solutions: a marketed micellar solution containing polyoxyl-35 castor oil (Daktarin ... [more ▼]

The pharmacokinetics of miconazole were studied after intravenous administration to six sheep (4 mg/kg) of three aqueous solutions: a marketed micellar solution containing polyoxyl-35 castor oil (Daktarin IV(R)) was compared with two solutions both containing 50 mM lactic acid and a cyclodextrin derivative (100 mM HP-betaCD or 50 mM SBE7-betaCD). The aim of this work was to demonstrate that these cyclodextrin derivatives (CDs) have no effect on the pharmacokinetics of miconazole by comparison with the micellar solution. The plasma concentration time curves have shown that there is no significant difference between the three solutions. [less ▲]

Detailed reference viewed: 12 (2 ULg)
See detailA Comparative Study of the Antimycotic Activity of a Miconazole Hp-Beta Cyclodextrin Solution and a Surfactant Solution
Piel, Géraldine ULg; Hayette, Marie-Pierre ULg; Evrard, Brigitte ULg et al

in Journal de Pharmacie de Belgique (1999), 54(3, May-Jun), 87-8

The antimycotic activity of a new parenteral solution containing miconazole was compared to that of a marketed solution (Daktarin IV solution). This solution has been withdrawn from the belgian market ... [more ▼]

The antimycotic activity of a new parenteral solution containing miconazole was compared to that of a marketed solution (Daktarin IV solution). This solution has been withdrawn from the belgian market probably because of the toxic effects related to the presence of polyoxyl 35 castor oil. We propose a new formulation containing 10 mg of miconazole per ml (as the marketed solution), in combination with HP-beta cyclodextrin and lactic acid. The MIC of these two solutions were determined by broth microdilution method (following the NCCLS guidelines) against 15 yeasts and 16 filamentous fungi isolates. This study showed that MIC obtained with these two solutions are not significantly different. In vitro, the cyclodextrin solution has the same antimycotic activity as the Daktarin IV solution and can be proposed as a safe and effective parenteral solution to replace the previous surfactant solution. [less ▲]

Detailed reference viewed: 38 (7 ULg)
Peer Reviewed
See detailThe effect of hydroxypropyl-b-cyclodextrins on the pharamacokinetics of albendazole in sheep
Evrard, Brigitte ULg; De Tullio, Pascal ULg; Chiap, Patrice ULg et al

in Proceedings of 26th International Symposium on Controlled Release of Bioactive Materials (1999)

Detailed reference viewed: 9 (0 ULg)